公开(公告)号：US10000451B2

公开(公告)日：2018-06-19

申请号：US15650902

申请日：2017-07-15

Applicant: SRI INTERNATIONAL

Inventor： Ling Jong ,  Chih-Tsung Chang ,  Jaehyeon Park

IPC: C07D403/02 ,  A61K31/404 ,  C07D209/14 ,  C07D209/12 ,  C07D405/02

CPC classification number: C07D209/14 ,  A61K31/404 ,  C07D209/08 ,  C07D209/12 ,  C07D209/30 ,  C07D403/02 ,  C07D403/06 ,  C07D405/02 ,  C07D405/06 ,  C07D471/04

Abstract: The invention provides mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) inhibitors, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant diminution of tumor cell growth, cancer or metastasis.

公开(公告)号：US20170320824A1

公开(公告)日：2017-11-09

申请号：US15650902

申请日：2017-07-15

Applicant: SRI INTERNATIONAL

Inventor： Ling Jong ,  Chih-Tsung Chang ,  Jaehyeon Park

IPC: C07D209/14 ,  C07D209/12 ,  C07D403/02 ,  C07D405/02

CPC classification number: C07D209/14 ,  A61K31/404 ,  C07D209/08 ,  C07D209/12 ,  C07D209/30 ,  C07D403/02 ,  C07D403/06 ,  C07D405/02 ,  C07D405/06 ,  C07D471/04

Abstract: The invention provides mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) inhibitors, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant diminution of tumor cell growth, cancer or metastasis.